Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORSAR
NCT07440238Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of prednisone in septic arthritis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Functional joint outcomes at 24 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
prednisone
03
Conditions
septic arthritis
Beyond the preview
Go deeper on NCT07440238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07440238.